Simcere Pharmaceutical Group Limited
SMHGF
$0.6486
-$0.0621-8.74%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 244.78M | 245.97M | 214.98M | 216.84M | 223.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 244.78M | 245.97M | 214.98M | 216.84M | 223.41M |
| Cost of Revenue | 45.81M | 46.03M | 44.99M | 45.38M | 55.63M |
| Gross Profit | 198.98M | 199.94M | 169.99M | 171.46M | 167.78M |
| SG&A Expenses | 114.39M | 114.94M | 95.60M | 96.43M | 93.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -12.35M | -12.40M | -4.94M | -4.98M | -4.72M |
| Total Operating Expenses | 206.51M | 207.51M | 174.74M | 176.26M | 198.97M |
| Operating Income | 38.27M | 38.46M | 40.23M | 40.58M | 24.44M |
| Income Before Tax | 22.60M | 22.71M | 34.16M | 34.45M | -109.70M |
| Income Tax Expenses | 3.38M | 3.40M | 2.63M | 2.65M | -1.75M |
| Earnings from Continuing Operations | 19.22M | 19.32M | 31.53M | 31.80M | -107.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 0.00 |
| Net Income | 19.22M | 19.32M | 31.53M | 31.80M | -107.95M |
| EBIT | 38.27M | 38.46M | 40.23M | 40.58M | 24.44M |
| EBITDA | 46.25M | 46.47M | 47.72M | 48.13M | 31.72M |
| EPS Basic | 0.01 | 0.01 | 0.01 | 0.01 | -0.04 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.01 | 0.01 | 0.01 | 0.01 | -0.04 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 2.47B | 2.47B | 2.55B | 2.55B | 2.60B |
| Average Diluted Shares Outstanding | 2.49B | 2.49B | 2.55B | 2.55B | 2.60B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 145.17% | 145.17% | -- | -- | -26.89% |